The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy
Open Access
- 20 February 2013
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (4) , 1130-1132
Abstract
The standard first-line treatment of metastatic non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor is platinum-based chemotherapy, although characterized by great interindividual variation in outcomes. The identification of molecular markers predictive of sensitivity to platinum could thus considerably improve patient care.Keywords
This publication has 3 references indexed in Scilit:
- Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclassesAnnals of Oncology, 2012
- Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA ExpressionPLOS ONE, 2009
- BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancerHuman Molecular Genetics, 2004